6278

    531146

    MEDICAMEQ

    img img img img
    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    MEDICAMEN BIOTECH LIMITED Share Price Today

    MEDICAMEN BIOTECH LIMITED is currently trading at ₹243.55, up by ₹1.69 from the previous close. The stock touched an intraday high of ₹245.90 and a low of ₹242.90 during the latest trading session. Over the past one year, MEDICAMEN BIOTECH LIMITED has delivered a loss of 38.35%, while the stock has gained 5.42% in the last one month.

    MEDICAMEN BIOTECH LIMITED performance

    Today’s low Today’s high
    ₹ 242.90 ₹ 245.90
    ₹ 241.85
    52 week low 52 week high
    ₹ 212.40 ₹ 447.65
    ₹ 241.85
    Open Price ₹ 243.60
    Prev. Close ₹ 241.85
    Volume (Shares) 14741.00
    Total traded value ₹ 35.65
    Upper Circuit ₹ 290.20
    Lower Circuit ₹ 193.50
    info

    Investment Returns

    Over 1 Month 5.42% Over 3 Months -6.13% Over 6 Months -31.91% Over 1 Year -38.35%
    demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    MEDICAMEN BIOTECH LIMITED fundamentals


    • Market cap (Cr) 328.00
    • P/E Ratio (TTM) 34.90
    • Beta 0.93
    • Book Value / share 206.24
    • Return on equity 4.43%
    • EPS (TTM) 6.94
    • Dividend yield 0.41%
    • Net profit/quarter (Cr) 2.97
    info icon alternate text
    • Market cap (Cr) 328.50
    • P/E Ratio (TTM) 34.90
    • Beta 0.72
    • Book Value / share 206.24
    • Return on equity 4.43%
    • EPS (TTM) 6.94
    • Dividend yield 0.41%
    • Net profit/quarter (Cr) 2.97
    info icon alternate text

    MEDICAMEN BIOTECH LIMITED Financials

    • Key Results
    • Key Ratios
    • Balance sheet
    • Cash Flow
    • Competition
    Open financial information
    Revenue
    Net income
    Particulars MAR 2026 (Values in Cr)
    Revenue 54.68
    Operating Expense 52.88
    Net Profit 2.97
    Net Profit Margin (%) 5.43
    Earnings Per Share (EPS) 2.19
    EBITDA 5.85
    Effective Tax Rate (%) 15.86
    Particulars DEC 2025 (Values in Cr)
    Revenue 43.49
    Operating Expense 40.94
    Net Profit 2.59
    Net Profit Margin (%) 5.95
    Earnings Per Share (EPS) 1.91
    EBITDA 5.61
    Effective Tax Rate (%) 15.90
    Particulars SEP 2025 (Values in Cr)
    Revenue 42.23
    Operating Expense 39.83
    Net Profit 2.21
    Net Profit Margin (%) 5.23
    Earnings Per Share (EPS) 1.63
    EBITDA 5.42
    Effective Tax Rate (%) 20.21
    Particulars JUN 2025 (Values in Cr)
    Revenue 38.45
    Operating Expense 36.75
    Net Profit 1.64
    Net Profit Margin (%) 4.26
    Earnings Per Share (EPS) 1.21
    EBITDA 4.50
    Effective Tax Rate (%) 24.42
    Particulars MAR 2025 (Values in Cr)
    Revenue 26.00
    Operating Expense 28.18
    Net Profit 2.41
    Net Profit Margin (%) 9.26
    Earnings Per Share (EPS) 1.90
    EBITDA 4.13
    Effective Tax Rate (%) 20.72
    Particulars MAR 2026 (Values in Cr)
    Revenue 178.85
    Operating Expense 170.40
    Net Profit 9.41
    Net Profit Margin (%) 5.26
    Earnings Per Share (EPS) 6.94
    EBITDA 21.39
    Effective Tax Rate (%) 18.52
    Particulars MAR 2025 (Values in Cr)
    Revenue 151.46
    Operating Expense 144.92
    Net Profit 9.45
    Net Profit Margin (%) 6.23
    Earnings Per Share (EPS) 7.43
    EBITDA 22.78
    Effective Tax Rate (%) 26.07
    Particulars MAR 2024 (Values in Cr)
    Revenue 172.39
    Operating Expense 157.79
    Net Profit 13.30
    Net Profit Margin (%) 7.71
    Earnings Per Share (EPS) 10.50
    EBITDA 28.28
    Effective Tax Rate (%) 21.25
    Particulars MAR 2023 (Values in Cr)
    Revenue 137.88
    Operating Expense 123.01
    Net Profit 15.00
    Net Profit Margin (%) 10.87
    Earnings Per Share (EPS) 12.04
    EBITDA 26.60
    Effective Tax Rate (%) 13.44
    Particulars MAR 2022 (Values in Cr)
    Revenue 115.45
    Operating Expense 99.06
    Net Profit 14.91
    Net Profit Margin (%) 12.91
    Earnings Per Share (EPS) 12.20
    EBITDA 25.27
    Effective Tax Rate (%) 17.67
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 167.57
    ROE % 3.12
    ROCE % 5.56
    Total Debt to Total Equity 0.15
    EBITDA Margin 12.72
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 162.79
    ROE % 4.74
    ROCE % 8.14
    Total Debt to Total Equity 0.14
    EBITDA Margin 14.41
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 150.82
    ROE % 8.67
    ROCE % 10.36
    Total Debt to Total Equity 0.15
    EBITDA Margin 19.02
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 119.89
    ROE % 10.67
    ROCE % 12.27
    Total Debt to Total Equity 0.16
    EBITDA Margin 22.36
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 108.78
    ROE % 9.55
    ROCE % 12.49
    Total Debt to Total Equity 0.12
    EBITDA Margin 18.12
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 171.17
    ROE % 4.43
    ROCE % 6.71
    Total Debt to Total Equity 0.13
    EBITDA Margin 15.41
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 164.54
    ROE % 6.60
    ROCE % 9.76
    Total Debt to Total Equity 0.14
    EBITDA Margin 17.14
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 152.30
    ROE % 8.78
    ROCE % 10.45
    Total Debt to Total Equity 0.15
    EBITDA Margin 19.64
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 121.18
    ROE % 10.56
    ROCE % 12.17
    Total Debt to Total Equity 0.16
    EBITDA Margin 22.36
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 109.98
    ROE % 9.73
    ROCE % 12.62
    Total Debt to Total Equity 0.12
    EBITDA Margin 18.87
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 3.75
    Total Assets 297.15
    Total Liabilities 297.15
    Total Equity 213.05
    Share Outstanding 1
    Price to Book Ratio 2.81
    Return on Assets (%) 2.39
    Return on Capital (%) 2.89
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 14.78
    Total Assets 294.55
    Total Liabilities 294.55
    Total Equity 206.98
    Share Outstanding 1
    Price to Book Ratio 2.33
    Return on Assets (%) 3.71
    Return on Capital (%) 4.6
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 20.77
    Total Assets 278.51
    Total Liabilities 278.51
    Total Equity 193.41
    Share Outstanding 1
    Price to Book Ratio 4.30
    Return on Assets (%) 5.32
    Return on Capital (%) 6.82
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 3.82
    Total Assets 225.69
    Total Liabilities 225.69
    Total Equity 146.46
    Share Outstanding 1
    Price to Book Ratio 5.31
    Return on Assets (%) 6.60
    Return on Capital (%) 8.72
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 3.89
    Total Assets 193.72
    Total Liabilities 193.72
    Total Equity 132.88
    Share Outstanding 1
    Price to Book Ratio 4.86
    Return on Assets (%) 6.26
    Return on Capital (%) 8.07
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 3.58
    Total Assets 293.18
    Total Liabilities 293.18
    Total Equity 217.63
    Share Outstanding 1
    Price to Book Ratio 2.81
    Return on Assets (%) 3.22
    Return on Capital (%) 3.86
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 14.62
    Total Assets 294.21
    Total Liabilities 294.21
    Total Equity 209.20
    Share Outstanding 1
    Price to Book Ratio 2.33
    Return on Assets (%) 4.51
    Return on Capital (%) 5.57
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 20.44
    Total Assets 276.78
    Total Liabilities 276.78
    Total Equity 193.79
    Share Outstanding 1
    Price to Book Ratio 4.30
    Return on Assets (%) 5.42
    Return on Capital (%) 6.88
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 3.81
    Total Assets 225.69
    Total Liabilities 225.69
    Total Equity 148.03
    Share Outstanding 1
    Price to Book Ratio 5.31
    Return on Assets (%) 6.60
    Return on Capital (%) 8.65
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 3.08
    Total Assets 192.18
    Total Liabilities 192.18
    Total Equity 134.35
    Share Outstanding 1
    Price to Book Ratio 4.86
    Return on Assets (%) 6.49
    Return on Capital (%) 8.23
    Particulars MAR 2025 (Values in Cr)
    Net Income 6.55
    Cash from Operations -6.80
    Cash from Investing -1.39
    Cash from Financing -1.47
    Net change in Cash -11.02
    Free Cash Flow -4.62
    Particulars MAR 2024 (Values in Cr)
    Net Income 9.49
    Cash from Operations -3.67
    Cash from Investing -5.56
    Cash from Financing 6.31
    Net change in Cash -5.99
    Free Cash Flow 2.60
    Particulars MAR 2023 (Values in Cr)
    Net Income 14.72
    Cash from Operations -3.16
    Cash from Investing -5.88
    Cash from Financing 29.12
    Net change in Cash 16.95
    Free Cash Flow 3.43
    Particulars MAR 2022 (Values in Cr)
    Net Income 14.89
    Cash from Operations 7.30
    Cash from Investing -8.47
    Cash from Financing 4.29
    Net change in Cash -0.06
    Free Cash Flow 15.91
    Particulars MAR 2021 (Values in Cr)
    Net Income 12.12
    Cash from Operations 17.23
    Cash from Investing -17.81
    Cash from Financing 5.83
    Net change in Cash 0.79
    Free Cash Flow 35.19
    Particulars MAR 2025 (Values in Cr)
    Net Income 9.44
    Cash from Operations -1.28
    Cash from Investing -1.72
    Cash from Financing -6.68
    Net change in Cash -11.04
    Free Cash Flow 0.62
    Particulars MAR 2024 (Values in Cr)
    Net Income 13.29
    Cash from Operations 2.81
    Cash from Investing -8.71
    Cash from Financing 3.13
    Net change in Cash -5.82
    Free Cash Flow 8.56
    Particulars MAR 2023 (Values in Cr)
    Net Income 15.00
    Cash from Operations -6.62
    Cash from Investing -7.54
    Cash from Financing 27.66
    Net change in Cash 16.62
    Free Cash Flow -0.37
    Particulars MAR 2022 (Values in Cr)
    Net Income 14.90
    Cash from Operations 8.01
    Cash from Investing -8.47
    Cash from Financing 4.39
    Net change in Cash 0.73
    Free Cash Flow 16.61
    Particulars MAR 2021 (Values in Cr)
    Net Income 12.48
    Cash from Operations 17.43
    Cash from Investing -17.81
    Cash from Financing 5.68
    Net change in Cash 0.85
    Free Cash Flow 35.40
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENTERPRISES L 32.45 13.46 1.57 248.68 23.12 38.85
    BLISS GVS PHARMA LTD 463.55 37.26 4.12 4916.24 118.35 552.90
    CIPLA LTD. 1410.90 31.85 3.31 113978.90 1165.55 1672.20
    FERMENTA BIOTECH LTD. 432.60 20.23 3.13 1273.18 256.40 480.00
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENTERPRISES L 32.45 22.69 4.18 248.68 23.12 38.85
    AMRUTANJAN HEALTH CARE LTD. 510.50 22.88 3.98 1475.89 490.00 789.95
    ASTRAZENECA PHARMA IND LT 8000.10 104.55 22.91 20000.25 7630.00 9850.00
    BLISS GVS PHARMA LTD 463.55 50.11 4.25 4916.24 118.35 552.90

    MEDICAMEN BIOTECH LIMITED shareholding pattern

    Holding
    59.06%
    40.45%
    0.07%
    0.4%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    News

    Left Arrow
    Right Arrow

    MEDICAMEN BIOTECH LIMITED Technicals Summary

    • EMA & SMA
    • Resistance and Support
    • Delivery and Volume
    • Beta
    • Price Change Analysis
    241.85 1.76 redarrow
    red-green-graph indicator
    11 Bearish
    5 Bullish
    • 5 Days 241.40
    • 26 Days 243.30
    • 10 Days 241.60
    • 50 Days 248.70
    • 12 Days 241.80
    • 100 Days 266.30
    • 20 Days 242.50
    • 200 Days 301.10
    239.33 PIVOT
    First Support 233.67 First Resistance 243.32 Second Support 229.68 Second Resistance 248.98 Third Support 224.02 Third Resistance 252.97
    RSI 48.89 ADX 25.20 MACD -1.53 Williams % R -56.32 Commodity Channel Index (CCI) -56.65
    Date 2026-07-24 Week 10524.00 Same Day 9514.00 Month 18652.00
    1 Year 0.93 3 Year 1.16
    Over 1 Month
    5.42% down
    Over 1 Year
    -38.35% down
    Over 3 Months
    -6.13% down
    Over 3 Years
    -32.78% down
    Over 6 Months
    -31.91% down
    Over 5 Years
    -15.21% down

    MEDICAMEN BIOTECH LIMITED Corporate Actions

    Dividend date Dividend amount Dividend type Record date Instrument type
    19 Sep 2025 1.0 Final 19 Sep 2025 Equity shares
    19 Sep 2024 1.0 Final 19 Sep 2024 Equity shares
    20 Sep 2023 1.0 Final 21 Sep 2023 Equity shares
    19 Sep 2022 1.0 Final 21 Sep 2022 Equity shares
    16 Sep 2021 1.0 Final 19 Sep 2021 Equity shares
    17 Sep 2020 0.5 Final 19 Sep 2020 Equity shares
    17 Sep 2019 1.0 Final 18 Sep 2019 Equity shares
    08 Aug 2017 1.0 Interim 09 Aug 2017 Equity shares
    21 Sep 2010 0.75 Final 23 Sep 2010 Equity shares
    Dividend date Dividend amount Dividend type Record date Instrument type
    19 Sep 2025 1.0 Final 19 Sep 2025 Equity shares
    19 Sep 2024 1.0 Final 19 Sep 2024 Equity shares
    20 Sep 2023 1.0 Final 21 Sep 2023 Equity shares
    19 Sep 2022 1.0 Final 21 Sep 2022 Equity shares
    16 Sep 2021 1.0 Final 19 Sep 2021 Equity shares
    17 Sep 2020 0.5 Final 19 Sep 2020 Equity shares
    17 Sep 2019 1.0 Final 18 Sep 2019 Equity shares
    08 Aug 2017 1.0 Interim 09 Aug 2017 Equity shares
    21 Sep 2010 0.75 Final 23 Sep 2010 Equity shares

    Top Gainers

    Top Losers

    stock
    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Medicamen Biotech Ltd?

    Answer Field

    Medicamen Biotech Ltd share price is for NSE ₹ 243.55 & for BSE ₹ 0.00 as on Jul 27 2026 09:50 AM.

    What is the Market Cap of Medicamen Biotech Ltd Share?

    Answer Field

    The market cap of Medicamen Biotech Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jul 27 2026 09:50 AM.

    What is the 52 Week High and Low of Medicamen Biotech Ltd?

    Answer Field

    The 52 Week High and Low of Medicamen Biotech Ltd for NSE is ₹ 447.65 and ₹ 212.40 and for BSE is ₹ 454.00 and ₹ 216.00.

    What is 1 year return for Medicamen Biotech Ltd?

    Answer Field

    The 1 year returns on the stock has been -38.35%.

    What is the P/E Ratio of Medicamen Biotech Ltd Share?

    Answer Field

    As on Jul 27 2026 09:50 AM the price-to-earnings (PE) ratio for Medicamen Biotech Ltd share is 34.90.

    What is the PB ratio of Medicamen Biotech Ltd Share?

    Answer Field

    As on Jul 27 2026 09:50 AM, the price-to-book (PB) ratio for Medicamen Biotech Ltd share is 206.24.

    How to Buy Medicamen Biotech Ltd Share?

    Answer Field

    You can trade in Medicamen Biotech Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Medicamen Biotech Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Medicamen Biotech Ltd shares on the Bajaj Broking app, follow these steps:

    • Login to the Bajaj Broking App

    • Click on the Search Icon

    • Search “Medicamen Biotech Ltd”

    • Click on the BUY icon

    • Place a buy order specifying the desired quantity of shares.

    • Click BUY again to complete the purchase

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59
    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |